CMRX vs. VACC, BRNS, LFVN, ONCY, MIST, ANVS, PRPH, YS, QTTB, and SPRO
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Vaccitech (VACC), Barinthus Biotherapeutics (BRNS), LifeVantage (LFVN), Oncolytics Biotech (ONCY), Milestone Pharmaceuticals (MIST), Annovis Bio (ANVS), ProPhase Labs (PRPH), YS Biopharma (YS), Q32 Bio (QTTB), and Spero Therapeutics (SPRO). These companies are all part of the "pharmaceutical preparations" industry.
Chimerix (NASDAQ:CMRX) and Vaccitech (NASDAQ:VACC) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, media sentiment, profitability, earnings, institutional ownership, community ranking, valuation, dividends and risk.
Chimerix has a beta of 1.13, suggesting that its share price is 13% more volatile than the S&P 500. Comparatively, Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500.
Chimerix received 369 more outperform votes than Vaccitech when rated by MarketBeat users. However, 70.83% of users gave Vaccitech an outperform vote while only 63.91% of users gave Chimerix an outperform vote.
Vaccitech has a net margin of -409.18% compared to Chimerix's net margin of -25,337.96%. Vaccitech's return on equity of -23.41% beat Chimerix's return on equity.
In the previous week, Chimerix and Chimerix both had 2 articles in the media. Vaccitech's average media sentiment score of 0.73 beat Chimerix's score of 0.00 indicating that Vaccitech is being referred to more favorably in the news media.
Chimerix currently has a consensus price target of $8.00, indicating a potential upside of 710.13%. Vaccitech has a consensus price target of $7.63, indicating a potential upside of 52.50%. Given Chimerix's stronger consensus rating and higher possible upside, equities analysts clearly believe Chimerix is more favorable than Vaccitech.
45.4% of Chimerix shares are held by institutional investors. Comparatively, 26.1% of Vaccitech shares are held by institutional investors. 10.0% of Chimerix shares are held by insiders. Comparatively, 6.0% of Vaccitech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Vaccitech has higher revenue and earnings than Chimerix. Vaccitech is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks.
Summary
Chimerix beats Vaccitech on 10 of the 17 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
